ResearcherNational Institute of Genomic MedicineActive in the last 2 years
Jorge Meléndez-Zajgla
Matched on ORCID iD 0000-0002-2209-1607; OpenAlex author ID A5088508201. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 6
2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 6
- Pancreatic Cancer Stem Cells Co-Expressing SOX2, OCT4, and TERT high Represent an Aggressive Subpopulation. Last author DOI 10.3390/cells15020129↗
- Defensin-Rich Platelets Drive Pro-Tumorigenic Programs in Pancreatic Adenocarcinoma. Last author DOI 10.3390/ijms262210898↗
- Tumor Microenvironment Role in Pancreatic Cancer Stem Cells. Last author DOI 10.3390/cells12121560↗
- Pancreatic Cancer Cells Induce MicroRNA Deregulation in Platelets. Co-author DOI 10.3390/ijms231911438↗
- The Role of lncRNAs in the Stem Phenotype of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms22126374↗
- Precision Oncology in Pancreatic Cancer. From Surgery- to Genetic-Based Chemotherapy. First author DOI 10.24875/ric.20000233↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Vilma Maldonado · 5 shared papers, 2021–2026 · strength 1.40
- Paper Pancreatic Cancer Stem Cells Co-Expressing SOX2, OCT4, and TERT high Represent an Aggressive Subpopulation. DOI 10.3390/cells15020129↗
- Paper The Role of lncRNAs in the Stem Phenotype of Pancreatic Ductal Adenocarcinoma. DOI 10.3390/ijms22126374↗
- Paper Defensin-Rich Platelets Drive Pro-Tumorigenic Programs in Pancreatic Adenocarcinoma. DOI 10.3390/ijms262210898↗
- Ismael Domínguez-Rosado · 2 shared papers, 2020–2022 · strength 0.44
- Erika Curiel-Gomez · 1 shared paper, 2026 · strength 0.39
- Jonathan González-Ruíz · 1 shared paper, 2025 · strength 0.27
- Aaron Galindo-Vega · 1 shared paper, 2023 · strength 0.26
- Jorge Yassen Díaz-Blancas · 1 shared paper, 2022 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.